Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms Publisher Pubmed

Moslehi M¹ ; Rezaei S² ; Talebzadeh P³ ; Ansari MJ⁴ ; Jawad MA⁵ ; Jalil AT⁶ ; Rastegarpouyani N⁷ ; Jafarzadeh E⁷ ; Taeb S^{8, 9} ; Najafi M¹⁰

Source: Clinical and Experimental Pharmacology and Physiology Published:2023

Abstract

The incidence of cancer has been growing worldwide. Better survival rates following the administration of novel drugs and new combination therapies may concomitantly cause concern regarding the long-term adverse effects of cancer therapy, for example, second primary malignancies. Moreover, overcoming tumour resistance to anticancer agents has been long considered as a critical challenge in cancer research. Some low toxic adjuvants such as herb-derived molecules may be of interest for chemoprevention and overcoming the resistance of malignancies to cancer therapy. Apigenin is a plant-derived molecule with attractive properties for chemoprevention, for instance, promising anti-tumour effects, which may make it a desirable adjuvant to reduce genomic instability and the risks of second malignancies among normal tissues. Moreover, it may improve the efficiency of anticancer modalities. This paper aims to review various effects of apigenin in both normal tissues and malignancies. In addition, we explain how apigenin may have the ability to protect usual cells against the genotoxic repercussions following radiotherapy and chemotherapy. Furthermore, the inhibitory effects of apigenin on tumours will be discussed. © 2022 John Wiley & Sons Australia, Ltd.

Related Docs

View other Related Docs

1. Modulation of the Immune System by Melatonin; Implications for Cancer Therapy, International Immunopharmacology (2022)

2. The Significant Impact of Apigenin on Different Aspects of Autoimmune Disease, Inflammopharmacology (2018)

3. Evaluation of the Osteogenic Effect of Apigenin on Human Mesenchymal Stem Cells by Inhibiting Inflammation Through Modulation of Nf-Κb/Iκbα, Research in Pharmaceutical Sciences (2022)

Experts (# of related papers)

View all Related Experts

Mustafa Ghanadian (1)

Mahmoud Etebari (1)

Other Related Docs

4. Targeting Glioma Cells With Nutraceuticals: Therapeutic Effects Based on Molecular Mechanisms, New Evidence and Perspectives, Mini-Reviews in Medicinal Chemistry (2023)

5. Anti-Inflammatory Effect of Apigenin and Hydroalcoholic Extract of Dracocephalum Kotschyi on Acetic Acid-Induced Colitis in Rats, Research in Pharmaceutical Sciences (2017)

6. The Role of Curcumin in Modulating Circular Rnas and Long Non-Coding Rnas in Cancer, Clinical and Translational Oncology (2024)

7. Evaluation of Protective Effect of Amifostine on Dacarbazine Induced Genotoxicity, Research in Pharmaceutical Sciences (2015)

8. Radiation-Induced Testicular Damage in Mice: Protective Effects of Apigenin Revealed by Histopathological Evaluation, Current Radiopharmaceuticals (2024)

9. Cytotoxic and Apoptotic Effects of Flavonoids and a Geraniol Derivative From Artemisia Kermanensis on Normal and Breast Cancer Cell Lines, Research Journal of Pharmacognosy (2022)

10. Flavonoids Target Different Molecules of Autophagic and Metastatic Pathways in Cancer Cells, Cancer Cell International (2023)

11. Curcumin: A New Candidate for Melanoma Therapy?, International Journal of Cancer (2016)

12. Natural and Herbal Compounds Targeting Breast Cancer, a Review Based on Cancer Stem Cells, Iranian Journal of Basic Medical Sciences (2020)

Style	Citing Format
MLA	Moslehi M, et al.. "Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms." Clinical and Experimental Pharmacology and Physiology, vol. 50, no. 1, 2023, pp. 3-18.
APA	Moslehi M, Rezaei S, Talebzadeh P, Ansari MJ, Jawad MA, Jalil AT, Rastegarpouyani N, Jafarzadeh E, Taeb S, Najafi M (2023). Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms. Clinical and Experimental Pharmacology and Physiology, 50(1), 3-18.
Chicago	Moslehi M, Rezaei S, Talebzadeh P, Ansari MJ, Jawad MA, Jalil AT, Rastegarpouyani N, Jafarzadeh E, Taeb S, Najafi M. "Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms." Clinical and Experimental Pharmacology and Physiology 50, no. 1 (2023): 3-18.
Harvard	Moslehi M et al. (2023) 'Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms', Clinical and Experimental Pharmacology and Physiology, 50(1), pp. 3-18.
Vancouver	Moslehi M, Rezaei S, Talebzadeh P, Ansari MJ, Jawad MA, Jalil AT, et al.. Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms. Clinical and Experimental Pharmacology and Physiology. 2023;50(1):3-18.
BibTex	@article{ author = {Moslehi M and Rezaei S and Talebzadeh P and Ansari MJ and Jawad MA and Jalil AT and Rastegarpouyani N and Jafarzadeh E and Taeb S and Najafi M}, title = {Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms}, journal = {Clinical and Experimental Pharmacology and Physiology}, volume = {50}, number = {1}, pages = {3-18}, year = {2023} }
RIS	TY - JOUR AU - Moslehi M AU - Rezaei S AU - Talebzadeh P AU - Ansari MJ AU - Jawad MA AU - Jalil AT AU - Rastegarpouyani N AU - Jafarzadeh E AU - Taeb S AU - Najafi M TI - Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms JO - Clinical and Experimental Pharmacology and Physiology VL - 50 IS - 1 SP - 3 EP - 18 PY - 2023 ER -

Science Communicator Platform

Authors

Abstract